JPRN-jRCTs071180055招募中2 期
Efficacy and safety of lacosamide in patients with erythromelalgia due to SCN9A gene mutation - Lacosamide for familial erythromelalgia
Takahashi Kenzo0 个研究点目标入组 6 人开始时间: 2019年3月18日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 15age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Older than 15 years
- •2.A case of erythromelalgia due to SCN9A gene mutation
- •3.A case who consent to informed consent
排除标准
- •1.A case with severe liver dysfunction(greater than Child-Pug Score C)2.A case with significant ECG abnormality(second-degree atrioventricular block,Brugada symdrome)
- •3.A case who is considered by a doctor to be inappropriate for administration of lacosamide.
研究者
相似试验
招募中
不适用
Efficacy and safety of lacosamide in patients with erythromelalgia due to SCN9A gene mutatioerythromelalgiaJPRN-UMIN000028778niversity of the Ryukyus Hospital1
进行中（未招募）
1 期
Efficacy, safety and tolerability of lacosamide in patients with small fiber neuropathy with a mutation in sodiumchannel 1.7: a randomized, double-blind, placebo controlled, crossover trialSCN9A mutation related small fiber neuropathyEUCTR2013-001511-70-NLMaastricht University Medical Center
已完成
3 期
Efficacy of Lacosamide and Topiramate on Control of Neonatal Refractory SeizuresIRCT20230415057911N2Iran University of Medical Sciences54
招募中
Unknown
ORAL LACOSAMIDE AND ORAL TOPIRAMATE IN PREVENTING MIGRAINE ATTACKSMigraineIRCT20230809059091N1Combined Military Hospital Rahim Yar Khan250
进行中（未招募）
不适用
Safety and efficacy of levosimendan in patients with acute myocardial infarction complicated by symptomatic left ventricular failureEUCTR2004-002732-25-NOGeir Øystein Andersen, Department of Cardiology, Ulleval University Hospital